SkinBioTherapeutics to launch psoriasis targeting food supplement on October 29
AxisBiotix-Ps was described as delivering "tremendous results" for sufferers of the skin condition during a study conducted earlier this year
Company
SkinBioTherapeutics PLC
LON:SBTX
SkinBioTherapeutics PLC is a life science company focused on skin health. The company’s proprietary platform technology, SkinBiotix ® , is based upon discoveries made at The University of Manchester.
156 stories · page 2 of 8
SkinBioTherapeutics gears up for launch of psoriasis treatment in Q4; product could have applications across a range of skin conditions
AxisBiotix may have applications for eczema, acne and rosacea, the company said
Investment tips for 2021: small cap pick extends lead at half-way stage
All of the investments are in positive territory and all the tipsters are sticking with their current choices as they look to catch the leader
SkinBioTherapeutics says psoriasis study exceeds expectations as it moves into commercial phase for the food supplement
The breakthrough was developed by the company's subsidiary in collaboration with partner Winclove Probiotic
SkinBioTherapeutics targets oral care with University of Manchester collaboration
“This new strand to our development portfolio also presents near-term opportunities," said chief executive Stuart Ashman
SkinBioTherapeutics starts collaboration with University of Manchester to focus on skin inflammation treatments
The idea of the partnership is to find products ripe for commercialisation
Investment tips for 2021: small cap pick takes early lead in first quarter
We asked a group of market professionals and investment writers for their top picks for 2021 - this is the first update
Fintel slips after the release of its full-year results is delayed by a week
A look at some of the major movers in London on Monday
SkinBioTherapeutics expects significant progress in lead projects this year
The life sciences company had a comfortable cash position of £5.5mln as of December 31
SkinBioTherapeutics starts food supplement consumer study with more participants than planned
The additional 65 places are for patients suffering from non-psoriatic conditions to explore the possible impact of probiotics on other skin conditions
SkinBioTherapeutics continues working on its partnerships
Here we take a closer look at SkinBioTherapeutics, the life sciences group that is using bacteria to improve people’s skin
SkinBioTherapeutics expands food supplement study after receiving an "extraordinary" number of applications
A further 50 people will participate, taking the number to 250
SkinBioTherapeutics says AxisBiotix subsidiary has commenced enrolment for its food supplement consumer study
A proprietary blend of bacterial strains has been specifically designed to balance the gut microbiome to address the overproduction of new skin cells often seen in aggressive skin conditions such as psoriasis
SkinBioTherapeutics preparing to kick off psoriasis study as it eyes a busy year
Financially, the group remains well placed. It finished the 12 months to June 30, 2020, with £2.2mln in the bank and topped this up last month with a further £4.45mln from a placing and open offer
SkinBioTherapeutics boosts fundraise by £450,000 through open offer
Acceptances for the offer, which was priced at 16p, amounted to 2.8mln shares
SkinBioTherapeutics looks forward to first revenues in 2021
The junior life sciences firm is making good progress with Winclove Probiotics and Croda
SkinBioTherapeutics raises £4mln to accelerate development
As well as a placing at 16p a share, the firm has organised an open offer of stock that could bring in an additional £500,000
SkinBioTherapeutics appoints Dr Jonathan Sheffield as a senior medical advisor with immediate effect
Since 2010, Dr Sheffield formerly served as the CEO of the National Institute for Health Research (NIHR), Clinical Research Network, which delivers clinical research studies throughout the NHS in England covering primary, secondary and tert
SkinBioTherapeutics reports progress in cosmetic programme and food supplement trial
The ‘self managed’ psoriasis food supplement trial is expected to accelerate the timing of readout and allow for a “significantly earlier commercial launch than originally planned”
SkinBioTherapeutics targets the promising skin microbiome market
The life sciences firm studies how to enhance and reintroduce the good bacteria on the skin